carbon monoxide (HBI-002) / Hillhurst Biopharma 
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carbon monoxide (HBI-002) / Hillhurst Biopharma
NCT06144749: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Not yet recruiting
1/2
8
US
HBI-002
Hillhurst Biopharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
10/24
12/24
NCT03926819: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Completed
1
20
US
HBI-002
Hillhurst Biopharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
04/23
04/23

Download Options